Cue Biopharma (CUE) Receivables (2019 - 2025)

Cue Biopharma has disclosed Receivables across 7 years of filings, most recently posting $5.5 million for Q4 2025.

• Receivables for Q4 2025 came in at $5.5 million, up 486.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.5 million (up 486.88% YoY), and the FY2025 annual result was $5.5 million, up 486.88% from the prior year.
• Receivables came in at $5.5 million for Q4 2025 at Cue Biopharma, up from $387000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $5.5 million in Q4 2025 to a low of $57000.0 in Q4 2022.
• The 5-year median for Receivables is $1.1 million (2023), against an average of $1.5 million.
• Across the five-year window, Receivables tumbled 98.19% in 2022 and soared 2878.95% in 2023, its largest moves.
• Cue Biopharma's Receivables stood at $3.1 million in 2021, then tumbled by 98.19% to $57000.0 in 2022, then jumped by 2878.95% to $1.7 million in 2023, then plunged by 44.35% to $945000.0 in 2024, then surged by 486.88% to $5.5 million in 2025.
• The last three Receivables figures came in at $5.5 million (Q4 2025), $387000.0 (Q3 2025), and $532000.0 (Q2 2025), per Business Quant data.